Ginkgo Bioworks announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years. Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, the partners aim to improve the manufacturing of Novo Nordisk’s medicines for serious chronic diseases, including diabetes and obesity medications. The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk’s portfolio.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Ginkgo Bioworks, IdeeLab Biotechnology enter agreement
- Ginkgo Bioworks, Prozomix announce new partnership
- Ginkgo Bioworks acquires Modulus Therapeutics’ cell therapy platform assets
- Ginkgo Bioworks Acquires Modulus Therapeutics’ Cell Therapy Assets to Strengthen Next-Gen CAR Designs
- Largest borrow rate increases among liquid names